Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

LIC IPO Date 2022, Review, Price, Allotment, Analysis Details

By Jagat Joshi
May 16, 2022

LIC IPO date is fixed, the IPO is to hit the market on May 04, 2022 and will close on May 09, 2022. LIC IPO is going to be one of the biggest IPOs ever launched in India. LIC IPO DRHP filed for a full offer for sale, with no Fresh Issue. The government to sell a 3.5% stake via mega IPO. LIC IPO to raise around ₹21,008 crores via IPO that comprises fresh issue of – and offer for sale up to 221,374,920 equity shares of ₹10 each. The retail quota is 35% while QIB is 50% and HNI is 15%.

The LIC IPO will be one of the biggest IPOs in the Indian Market. The IPO is to list on NSE and BSE. The IPO is a part of the disinvestment of the Government stack in the company. It will a great opportunity for retail investors and employees to invest in the company for the longer-term and short term. As per the speculations, the LIC Policy Holders will get the quota to apply for the LIC IPO.

Life Insurance Corporation is controlling around 72% of the market and around 66% share of the total premium collection. The valuation of the company stayed around ₹9 Lakh to ₹10 Lakh crore. The company was founded way back in 1956. It’s a merger of 245 insurance companies. The company had a monopoly in life insurance till the 1990s, after that the government gives a chance to the private sector in life insurance. They have around 2000+ branches in India with 8 zonal offices situated in Delhi, Chennai, Mumbai, Bhopal, Hyderabad, Patna, Kanpur, and Kolkata. They have 100+ divisional offices, 1100+ mini offices, and 1500+ satellite offices. You can check LIC IPO subscription status and LIC IPO allotment status on their respective pages.

LIC IPO Important Details:

LIC has over 13 lakh agents who generate business and earn commissions.
LIC is one of the Highly Trusted Insurance Brands in India.
The company manages around 39 lakh crores of assets, utilizing these funds in the stock market and bonds.
LIC is the 5th largest global insurer in the World.
LIC has 2000+ branches, 100+ divisional offices, and 1500+ Satellite Offices.
Guide: How to Link PAN with LIC Policy
The LIC owns 4% of all stocks listed in India, They invest funds across stocks and bonds.
LIC operates globally, in Fiji, Mauritius, Bangladesh, Nepal, Singapore, Sri Lanka, UAE, Bahrain, Qatar, Kuwait, and the United Kingdom.
The Indian government plans to sell 221.4 million shares (3.5% stake, revised from 5% earlier).
Around 10% of the equity shares are reserved for LIC policyholders.
The discount is offered to LIC policy holders and retail investors.

LIC IPO Review (Good or Bad)

Apply
Good to Apply for Long Term

Brokerage Firm IPO Review

GEPL Capital: Apply
Nirmal Bang: Apply
Ventura Securities: Apply
Capital Market: May Apply
Hem Securities: Apply
Jainam Broking: Apply
Reliance Securities: Apply
Angel Broking: Not Rated
ICICI Direct: Not Rated
Geojit Financial Services: Apply
Choice Broking: Apply
Samco Securities: Apply
Swastika Investment: Apply for Long Term

LIC IPO Date & Price Band (Final)

LIC IPO Open:	04 May 2022
LIC IPO Close:	09 May 2022
LIC IPO Size:	Approx ₹21,008 Crores
Fresh Issue:	Approx – Crores
Offer for Sale:	Approx 221,374,920 Equity Shares
Face Value:	₹10 Per Equity Share
LIC IPO Price Band:	₹902 to ₹949 Per Share
LIC IPO Listing on:	BSE & NSE
Retail Quota:	35%
QIB Quota:	50%
NII Quota:	15%
Discount:	₹60 for Policy Holders ₹45 for Retail & Employees
DRHP Draft Prospectus:	Click Here
RHP Draft Prospectus:	Click Here

LIC IPO Market Lot Size

The LIC IPO minimum market lot is 15 shares with ₹14,235 application amount. The retail investors can apply up to 14 lots with 210 shares or ₹187,200 amount.

Minimum Lot Size:	Minimum 15 Shares for 1 lot
Minimum Amount:	₹14,235 for 1 lot
Maximum Lot Size:	Maximum 210 Shares for 14 lot
Maximum Amount:	₹199,290 for 14 lot

LIC IPO Application for Policyholders

Minimum Lot Size:	Minimum 15 Shares for 1 lot
Minimum Amount:	₹13,335 for 1 lot
Maximum Lot Size:	Maximum 210 Shares for 14 lot
Maximum Amount:	₹186,690 for 14 lot

LIC IPO Application for Retail & Employees

Minimum Lot Size:	Minimum 15 Shares for 1 lot
Minimum Amount:	₹13,560 for 1 lot
Maximum Lot Size:	Maximum 210 Shares for 14 lot
Maximum Amount:	₹189,840 for 14 lot

LIC IPO Allotment & Listing Dates

The LIC IPO date is 04 May 2022 and the close date is 09 May 2022. The LIC IPO allotment will be finalized on 12 May 2022 and the IPO listing on 17 May 2022.

Price Band Announcement:	27 April 2022
Anchor Investors Allotment:	02 May 2022
LIC IPO Open Date:	04 May 2022
LIC IPO Close Date:	09 May 2022
Basis of Allotment:	12 May 2022
Refunds:	13 May 2022
Credit to Demat Account:	16 May 2022
LIC IPO Listing Date:	17 May 2022

LIC IPO Form

How to apply for the LIC IPO? You can apply for LIC IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the LIC IPO in the Invest section. The other option is you can apply for LIC IPO via IPO forms download via NSE and BSE. Check out the LIC forms – click BSE Forms & NSE Forms blank IPO forms download, fill, and submit in your bank or with your broker.

LIC Company Financial Report

₹ in Crores
	Revenue	Expense	PAT
2019	₹2645	₹2.63	₹2627
2020	₹2731	₹1.24	₹2710
2021	₹2986	₹5.22	₹2974
2021 6M	₹1520	₹0.25	₹1504

LIC IPO Valuation – FY2021

Check LIC IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):	₹4.70 per Equity Share
Price/Earning P/E Ratio:	N/A
Return on Net Worth (RoNW):	45.65%
Net Asset Value (NAV):	10.30 per Equity Share

Peer Group

SBI Life Insurance Company
HDFC Life Insurance Company
ICICI Prudential Life Insurance Company

Company Promoters

The President of India, Acting Through The Ministry Of Finance, Government of India

LIC IPO Registrar

KFin Technologies Private Limited

Selenium, Tower B, Plot No- 31 and 32

Gachibowli, Financial District

Nanakramguda, Serilingampally

Hyderabad 500 032, Telangana, India

Tel: +91 40 6716 2222

E-mail: lic.ipo@kfintech.com

Investor Grievance ID: einward.ris@kfintech.com

Website: www.kfintech.com

Contact Person: M Murli Krishna

SEBI Registration Number: INR000000221

LIC IPO Allotment Status Check

Check LIC IPO allotment status on KFintech website allotment URL. Click Here

LIC IPO Lead Managers

Kotak Mahindra Capital Company Limited
Axis Capital Limited
BofA Securities India Limited
Citigroup Global Markets India Private Limited
Goldman Sachs (India) Securities Private Limited
ICICI Securities Limited
JM Financial Limited
J.P. Morgan India Private Limited
Nomura Financial Advisory and Securities (India) Private Limited
SBI Capital Markets Limited

Company Address

Life Insurance Corporation of India

Central office: Yogakshema, Jeevan Bima Marg,

Nariman Point, Mumbai 400 021,

Maharashtra, India

Contact Person: Pawan Agrawal

Company Secretary and Compliance Officer

Tel: +91 22 6659 8732

E-mail: Investors@licindia.com

Website: www.licindia.in

IRDAI Registration number: 512

LIC IPO FAQs

What is LIC IPO?

LIC IPO is a main-board IPO. They are going to raise ₹21,008 Crores via IPO. The issue is priced at ₹902 to ₹949 per equity share. The IPO is to be listed on BSE & NSE.

When LIC IPO will open?

The IPO is to open on 04 May 2022 for QIB, NII, and Retail Investors.

What is LIC IPO Investors Portion?

The investors’ portion for QIB-50%, NII-15%, and Retail 35%.

How to Apply the LIC IPO?

You can apply LIC IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the LIC IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “LIC”. Click on Bid Button. Enter your UPI ID, Quantity and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the LIC IPO through Upstox?

Log in to Upstox Application with your credentials. Select the IPO. You will see the IPO Name “LIC”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the LIC IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “LIC”. Click on Bid Button. Confirm your application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is LIC IPO Size?

LIC IPO size is ₹21,008 crores.

What is LIC IPO Price Band?

LIC IPO Price Band is ₹902 to ₹949.

What is LIC IPO Minimum and Maximum Lot Size?

The minimum bid is 15 Shares with ₹14,235 amount while the maximum bid is 210 shares with ₹199,290.

What is the LIC IPO Allotment Date?

LIC IPO allotment date is 12 May 2022.

What is the LIC IPO Listing Date?

LIC IPO listing date is 17 May 2022. The IPO is to list on BSE and NSE.

Note: The LIC IPO price band and date will be added as it will be officially announced. The IPO grey market premium (LIC IPO GMP) will be added on the IPO grey market page as it will start)

Follow IPO Watch for the Upcoming IPO news and their reviews, also keep following us on Twitter, Facebook, and Instagram. For our latest videos, subscribe to our YouTube channel.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.